Furthermore, circulating levels of MCP-1 in the serum of pancreatic cancer patients correlate with macrophage infiltration into tumors [29, 30], suggesting that both MCP-1 and TAMs may represent critical therapeutic targets in PDAC. Here, CCL2 is linked to pancreatic neoplasm.